Risks

A near-1.0 current ratio and 0.74 quick ratio leave SOLV less liquid than many healthcare-services peers, increasing refinancing and working-capital sensitivity if reimbursement timing tightens.

A 95.8-day cash conversion cycle, driven by 62.9 days of receivables and 100.8 days of inventory, creates more cash drag than asset-light peers and can constrain growth funding.

Net debt to EBITDA of 1.88x is manageable but still above net-cash or lower-leverage peers, so margin pressure or acquisition delays would reduce flexibility faster.

Interest coverage of 7.8x is adequate, yet it trails stronger-covered peers and leaves less cushion if payer mix, utilization, or labor costs weaken operating earnings.

Free cash flow remains negative on a TTM basis, which increases reliance on operating improvement or balance-sheet capacity to fund capex and working capital.

Opportunities

SOLV’s moderate leverage profile versus more indebted healthcare-services peers preserves capacity to fund growth and absorb volatility without immediate balance-sheet stress.

Interest coverage above 7x gives SOLV more earnings resilience than highly levered peers, supporting steadier execution if reimbursement or utilization conditions soften.

Working-capital discipline could unlock meaningful cash conversion upside because the 95.8-day cycle is long versus better-managed peers, improving reinvestment capacity.

If operating performance remains stable, SOLV can compare favorably with peers that carry heavier debt loads and weaker liquidity, enhancing relative positioning in a tighter funding environment.

Overall Score

SOLV scores Strong because leverage and coverage are manageable, but liquidity and working-capital intensity create peer-relative cash and flexibility risks that temper upside.